Methods and principles in medicinal chemistry, v. 6.
یادداشتهای مربوط به مندرجات
متن يادداشت
Rational Design of Bioactive Molecules Examples of Active Areas of Structure-Based Design From Renin to HIV-1 Protease Zinc Endoproteases: A Structural Superfamily Structure-Based Design of Potent Beta-Lactamase Inhibitors Inhibition of Sialidase Rational Design of Inhibitors of HIV-1 Reverse Transcriptase New Computational Approaches to Predict Protein-Ligand Interactions The Future of Structure-Based Design: A Worthy Precept?
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
Most drugs bind to a clearly defined macromolecular target that is complementary in terms of structure and chemistry. This observation is the basic paradigm of structure-based ligand design. Although this method first emerged in the 1980s, it has already become a powerful tool for pharmaceutical research. Much has been learned, however, since the first attempts to discover drugs on the basis of available biochemical and structural data. Nowadays, structure-based ligand design is an established method for creating drugs with new structural features, for modifying binding activities and pharmaco.
موضوع (اسم عام یاعبارت اسمی عام)
موضوع مستند نشده
Ligand binding (Biochemistry)
موضوع مستند نشده
Pharmaceutical chemistry.
موضوع مستند نشده
QSAR (Biochemistry)
رده بندی کنگره
شماره رده
QP624
.
75
.
D77
نشانه اثر
E358
1998
نام شخص به منزله سر شناسه - (مسئولیت معنوی درجه اول )